HC Wainwright & Co. Maintains Buy on ADC Therapeutics, Lowers Price Target to $12
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns maintains a Buy rating on ADC Therapeutics (NYSE:ADCT) but lowers the price target from $20 to $12.
June 20, 2023 | 2:35 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. maintains a Buy rating on ADC Therapeutics (NYSE:ADCT) but lowers the price target from $20 to $12.
The news of HC Wainwright & Co. maintaining a Buy rating on ADC Therapeutics is positive for the stock. However, the lowering of the price target from $20 to $12 may create uncertainty among investors, potentially offsetting the positive impact of the Buy rating. As a result, the short-term impact on the stock price is expected to be neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100